Dianthus Secures Orphan Status, Hits Early CIDP Go and Raises $719M
Dianthus secured FDA Orphan Drug Designation for claseprubart in myasthenia gravis and reached an early GO decision in its Phase 3 CAPTIVATE CIDP trial after achieving 20 responders with fewer than 40 participants. The company raised $719 million in an equity offering, boosting cash to $1.2 billion and extending runway into 2030.
1. Early GO Decision in CAPTIVATE CIDP Trial
Dianthus announced an early GO decision in the open-label Part A of its Phase 3 CAPTIVATE trial for chronic inflammatory demyelinating polyneuropathy after identifying 20 confirmed responders with fewer than the 40 planned participants. This interim success supports claseprubart’s potency and paves the way for Part B top-line guidance by year-end 2026.
2. Orphan Drug Designation and Phase 3 gMG Trial
The FDA granted Orphan Drug Designation for claseprubart in generalized myasthenia gravis, qualifying the therapy for trial tax credits, fee waivers and seven years of market exclusivity upon approval. Following an end-of-Phase 2 meeting, the company plans to initiate its registrational Phase 3 EMERGE trial evaluating 300 mg/2 mL Q2W and Q4W subcutaneous dosing in mid-2026, with top-line results expected in second half 2028.
3. DNTH212 Rheumatology Franchise Development
Dianthus selected Sjögren’s disease, systemic lupus erythematosus and dermatomyositis as the first three priority indications for its bifunctional fusion protein DNTH212, targeting BDCA2 and BAFF/APRIL pathways. This strategy aims to establish a complementary rheumatology franchise alongside its neuromuscular pipeline in gMG, CIDP and MMN.
4. Strengthened Balance Sheet and Cash Runway
The company generated approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants, increasing total cash to about $1.2 billion as of March 31, 2026. This financial position is projected to fund operations and clinical programs through 2030.